nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

11.03.2020 | Review Article

CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck

verfasst von: Camelia Billard-Sandu, Yun-Gan Tao, Marie-Paule Sablin, Gabriela Dumitrescu, David Billard, Eric Deutsch

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Addition of CDK4/6 inhibitors to a variety of established treatments in squamous cell carcinoma of the head and neck (SCCHN) has the potential to improve responses to other therapies and may help overcome treatment resistance. The SCCHN is a heterogeneous group of cancers of the oral cavity, the pharynx and the larynx with poor prognosis despite the aggressive multimodal therapies. In the past decade, significant advances were made in understanding of the molecular and genetic abnormalities leading to oncogenesis in SCCHN.

Recent findings

Besides EGFR targeting agents, antiangiogenic agents have been shown to produce antitumor activity in these tumors. The cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway regulates cellular proliferation by controlling the G1 to S cell cycle checkpoint. In SCCHN, the Rb pathway is frequently altered through amplification of CCND1 (cyclin D1) or deletion of CDKN2A (cyclin-dependent kinase inhibitor 2A) coding for p16INK4A, and thus promoting proliferation.

Summary

This article summarizes what we actually know of the place of CDK4/6 inhibitors in the therapeutic arsenal of SCCHN. CDK4/6 inhibitors could serve as a method to target these tumors, and both p16 loss and CCND1 amplification could be investigated as biomarkers.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127. https://doi.org/10.1056/NEJMoa0802656 CrossRefPubMed

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7 CrossRefPubMed

Cohen EEW, Soulières D, Tourneau CL, Dinis J, Licitra L, Ahn M-J et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156–167. https://doi.org/10.1016/S0140-6736(18)31999-8 CrossRefPubMed

Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867. https://doi.org/10.1056/NEJMoa1602252 CrossRefPubMedPubMedCentral

Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157–1160. https://doi.org/10.1126/science.1208130 CrossRefPubMedPubMedCentral

Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582. https://doi.org/10.1038/nature14129 CrossRef

Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res 14:366–369. https://doi.org/10.1158/1078-0432.CCR-07-1402 CrossRef

Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833–1841. https://doi.org/10.1016/j.celrep.2014.05.012 CrossRefPubMed

Zevallos JP, Yim E, Brennan P, Liu AY, Taylor JM, Weissler M et al (2016) Molecular profile of human papillomavirus-positive oropharyngeal squamous cell carcinoma stratified by smoking status. Int J Radiat Oncol Biol Phys 94:864. https://doi.org/10.1016/j.ijrobp.2015.12.022 CrossRef

10.

Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783. https://doi.org/10.1200/JCO.2005.03.7689 CrossRefPubMed

11.

Baker SJ, Reddy EP (2012) CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 3:658–669. https://doi.org/10.1177/1947601913478972 CrossRefPubMedPubMedCentral

12.

Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP (2010) Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle Georget Tex 9:689–699. https://doi.org/10.4161/cc.9.4.10611 CrossRef

13.

Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22. https://doi.org/10.1038/nrc2982 CrossRefPubMed

14.

Wreesmann VB, Singh B (2005) Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol 34:449–459. https://doi.org/10.1111/j.1600-0714.2005.00343.x CrossRef

15.

Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM et al (2013) Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3:770–781. https://doi.org/10.1158/2159-8290.CD-12-0537 CrossRefPubMed

16.

Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J et al (2011) CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS ONE 6:e26399. https://doi.org/10.1371/journal.pone.0026399 CrossRefPubMedPubMedCentral

17.

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35. https://doi.org/10.1056/NEJMoa0912217 CrossRefPubMedPubMedCentral

18.

Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21:1510–1517. https://doi.org/10.1038/sj.onc.1205214 CrossRefPubMed

19.

Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438PubMed

20.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ et al (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res BCR 11:R77. https://doi.org/10.1186/bcr2419 CrossRefPubMed

21.

Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R et al (2006) A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 66:7661–7667. https://doi.org/10.1158/0008-5472.CAN-06-1098 CrossRefPubMed

22.

Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS et al (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18:568–576. https://doi.org/10.1158/1078-0432.CCR-11-0509 CrossRef

23.

Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD et al (2011) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104:1862–1868. https://doi.org/10.1038/bjc.2011.177 CrossRefPubMedPubMedCentral

24.

Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D et al (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res Off J Am Assoc Cancer Res 19:6173–6182. https://doi.org/10.1158/1078-0432.CCR-13-1675 CrossRef

25.

Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V et al (2016) A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res Off J Am Assoc Cancer Res 22:5696–5705. https://doi.org/10.1158/1078-0432.CCR-16-1248 CrossRef

26.

Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck|Annals of Oncology|Oxford Academic n.d. https://academic.oup.com/annonc/article/27/suppl_6/1002P/2799758. Accessed 18 Mar 2019

27.

Ku BM, Yi SY, Koh J, Bae Y-H, Sun J-M, Lee S-H et al (2016) The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget 7:14803–14813. https://doi.org/10.18632/oncotarget.7543 CrossRefPubMedPubMedCentral

28.

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ et al (2014) Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 32:825–837. https://doi.org/10.1007/s10637-014-0120-7 CrossRefPubMedPubMedCentral

29.

Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S et al (2013) CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle Georget Tex 12:1091–1104. https://doi.org/10.4161/cc.24091 CrossRef

30.

Franco J, Witkiewicz AK, Knudsen ES (2014) CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 5:6512–6525. https://doi.org/10.1863/oncotarget.2270 CrossRefPubMedPubMedCentral

31.

McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E et al (2012) CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle Georget Tex 11:2747–2755. https://doi.org/10.4161/cc.21127 CrossRef

32.

Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 23:9408–9421. https://doi.org/10.1200/JCO.2005.01.5594 CrossRef

33.

Clark AS, O’Dwyer PJ, Heitjan D, Lal P, Feldman MD, Gallagher M et al (2014) A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. J Clin Oncol 32:527–527. https://doi.org/10.1200/jco.2014.32.15_suppl.527 CrossRef

34.

Ogawa K, Yoshioka Y, Isohashi F, Seo Y, Yoshida K, Yamazaki H (2013) Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res 33:747–754PubMed

35.

Hagen KR, Zeng X, Lee M-Y, Kahn ST, Pitner MKH, Zaky SS et al (2013) Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div 8:10. https://doi.org/10.1186/1747-1028-8-10 CrossRefPubMedPubMedCentral

36.

Han YK, Lee JH, Park GY, Chun SH, Han JY, Kim SD et al (2013) A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. Biochem Biophys Res Commun 430:1329–1333. https://doi.org/10.1016/j.bbrc.2012.10.119 CrossRefPubMed

Titel: CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck
verfasst von: Camelia Billard-Sandu
Yun-Gan Tao
Marie-Paule Sablin
Gabriela Dumitrescu
David Billard
Eric Deutsch
Publikationsdatum: 11.03.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 5/2020
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-020-05891-2

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck